{
    "ticker": "PRLD",
    "name": "Protalix BioTherapeutics, Inc.",
    "description": "Protalix BioTherapeutics, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of rare diseases. Founded in 2001, the company utilizes its proprietary ProCellEx platform, which is designed to produce therapeutic proteins in plant cells, offering an alternative to traditional methods of protein production. Protalix's lead product, Elelyso (taliglucerase alfa), is an enzyme replacement therapy approved for the treatment of Type 1 Gaucher disease, a rare genetic disorder. The company is committed to advancing its pipeline of product candidates, which includes therapies for other lysosomal storage disorders and additional rare diseases. By leveraging its unique platform and expertise in biologics development, Protalix aims to provide patients with effective and accessible treatment options while also addressing the unmet medical needs in the field of rare diseases. The company operates out of its headquarters in Carmiel, Israel, and is dedicated to enhancing the quality of life for patients through innovative therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Carmiel, Israel",
    "founded": "2001",
    "website": "http://www.protalix.com",
    "ceo": "Dror Bashan",
    "social_media": {
        "twitter": "https://twitter.com/ProtalixBio",
        "linkedin": "https://www.linkedin.com/company/protalix-biotherapeutics/"
    },
    "investor_relations": "http://www.protalix.com/investor-relations",
    "key_executives": [
        {
            "name": "Dror Bashan",
            "position": "CEO"
        },
        {
            "name": "Rami Elbassiouny",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Enzyme Replacement Therapies",
            "products": [
                "Elelyso"
            ]
        }
    ],
    "seo": {
        "meta_title": "Protalix BioTherapeutics, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore Protalix BioTherapeutics, Inc., a pioneer in biotechnology focused on enzyme replacement therapies for rare diseases. Learn about their innovative products and commitment to patient care.",
        "keywords": [
            "Protalix",
            "Biotechnology",
            "Rare Diseases",
            "Enzyme Replacement Therapy",
            "Elelyso"
        ]
    },
    "faq": [
        {
            "question": "What is Protalix BioTherapeutics known for?",
            "answer": "Protalix BioTherapeutics is known for its development of enzyme replacement therapies for rare diseases, particularly Gaucher disease."
        },
        {
            "question": "Who is the CEO of Protalix BioTherapeutics?",
            "answer": "Dror Bashan is the CEO of Protalix BioTherapeutics, Inc."
        },
        {
            "question": "Where is Protalix headquartered?",
            "answer": "Protalix is headquartered in Carmiel, Israel."
        },
        {
            "question": "What is Protalix's main product?",
            "answer": "Protalix's main product is Elelyso, an enzyme replacement therapy for Type 1 Gaucher disease."
        },
        {
            "question": "When was Protalix founded?",
            "answer": "Protalix was founded in 2001."
        }
    ],
    "competitors": [
        "AMGN",
        "SAGE",
        "ALNY"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "GILD",
        "BMY"
    ]
}